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SUMMARY
What is known and objective: Obesity affects approximately
one-third of the American population, and its prevalence
continues to increase. It is a signiﬁcant risk factor for cardiovas-
cular diseases and contributes to increased healthcare costs and
mortality. The objective is to review the current literature on the
cardiovascular effects of weight loss pharmacotherapy agents.
Methods: Literature was accessed through MEDLINE/PubMed
(up to April 2013) using the search terms obesity, weight loss,
pharmacotherapy, cardiovascular adverse effects and cardiovas-
cular side effects. References of the articles identiﬁed and www.
clinicaltrials.gov were also reviewed. Relevant guidelines,
review articles, clinical trials, meta-analyses, case series, FDA
documentation and prescribing information were included and
limited to English language articles.
Results and discussion: With the newly FDA-approved weight
loss pharmacotherapy, treatment options for obesity are more
diverse. However, safety concerns, including adverse cardiovas-
cular effects, have played a signiﬁcant role in the history of
weight loss pharmacotherapy and will likely play a role in the
future of the new agents, lorcaserin and phentermine/topira-
mate, as well.
What is new and conclusion: Long-term cardiovascular outcomes
studies with and without high-risk cardiovascular patients are
still needed for both lorcaserin and phentermine/topiramate
before these agents can be recommended in these patient
populations. It is yet to be determined whether modest weight
loss beneﬁt of these new agents outweighs the cardiovascular
risks.
WHAT IS KNOWN AND OBJECTIVE
The obesity epidemic affects a signiﬁcant portion of Americans,
and the prevalence of obesity continues to rise. In the early 1990s,
23% of Americans were considered obese; in 1999, the prevalence
had risen to 305%.1 Recent data suggest that approximately 36%
of adult Americans are obese.2 Obesity has been associated with
coronary artery disease, stroke, peripheral arterial disease, venous
thromboembolism, heart failure and hypertension.3,4 In 1998, the
American Heart Association reclassiﬁed obesity as a major,
modiﬁable risk factor for coronary heart disease. With its high
prevalence and associated risks, treatment of obesity is a signif-
icant healthcare target for intervention. Even modest weight loss of
5–10% is associated with improvements in cardiovascular (CV)
outcomes including blood glucose, blood pressure, triglycerides
and HDL.5 A 5% weight loss reduced the risk of developing new
type 2 diabetes mellitus by 58%.6,7
Medications are often used as adjunct therapy in the treatment of
obesity, along with lifestyle interventions, counselling and surgery.
The recently published AHA/ACC/TOS Guideline for the Man-
agement of Overweight and Obesity in Adults does not address
options in pharmacotherapy for weight loss. At the time of
guideline development, only orlistat was approved for weight loss.
The guidelines state ‘the provider should weigh the potential risks
of the medication being considered against the potential beneﬁts of
successful weight loss for the individual patient. The rationale for
use of medications is to help patients adhere to a lower calorie diet
more consistently in order to achieve sufﬁcient weight loss and
health improvements when combined with increased physical
activity. Medications work to reinforce lifestyle change and should
be prescribed as an adjunct to lifestyle interventions’when needed.8
However, anti-obesity medications are often plagued by high
rates of adverse effects, including adverse CV events. These events
include valvular heart disease, pulmonary hypertension, myocar-
dial infarctions and strokes. This review will examine the history
of CV effects of weight loss pharmacotherapy and assess the
newer, recently approved agents and the data on CV outcomes.
METHODS
Literature was accessed through MEDLINE/PubMed (up to April
2013) using the search terms obesity, weight loss, pharmacother-
apy, cardiovascular adverse effects and cardiovascular side effects.
References of the articles identiﬁed and www.clinicaltrials.gov
were also reviewed. Relevant guidelines, review articles, clinical
trials, meta-analyses, case series, FDA documentation and pre-
scribing information were included and limited to English
language articles.
RESULTS
Mechanisms of action of weight loss pharmacotherapy
While the exact mechanisms of weight loss agents are often
unknown, there are two proposed primary mechanisms of action
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for anti-obesity medications: peripherally acting and centrally
acting.9,10 Peripherally acting agents reduce fat absorption from
the gastrointestinal (GI) tract. For example, orlistat is a lipase
inhibitor that impedes the absorption of dietary fat from the GI
tract. Centrally acting agents may increase satiety through sero-
tonergic, noradrenergic or dopaminergic targets by blocking
reuptake or stimulating receptors in the satiety centre in the brain,
including the hypothalamus and limbic system.9,11 Agents may
either work peripherally or centrally to increase energy expendi-
ture by inducing thermogenesis or lipolysis as well.9 It is
hypothesized that sympathomimetic agents, such as phentermine,
work mainly in the central nervous system by increasing norepi-
nephrine in the synaptic cleft and directly stimulating receptors,
but some may increase thermogenesis as well.9,11 Ephedrine and
herbal ephedra may work primarily through thermogenesis and
lipolysis, but may work centrally as well.9,11
Many agents are often associated with adverse CV effects and
have been removed from the market as will be discussed.
However, a number of centrally acting sympathomimetic agents
are still available for short-term use including phentermine,
diethylpropion, benzphetamine and phendimetrazine.9,10
Pharmacotherapies withdrawn due to adverse cardiovascular
effects
Fenﬂuramine/Dexfenﬂuramine. Fenﬂuramine came to the market in
1973, followed by dexfenﬂuramine in 1996. Fenﬂuramine and
dexfenﬂuramine stimulate release of 5-hydroxytryptamine (5-HT)
and inhibit reuptake in the synaptic cleft.9 Dexfenﬂuramine was a
more selective D-isomer of fenﬂuramine and was boasted to have
fewer side effects than fenﬂuramine. Several randomized, con-
trolled trials demonstrated the weight loss beneﬁt of fenﬂuramine
alone or in combination with phentermine or dexfenﬂuramine
alone.12,13 However, these beneﬁts were marred by concerns for
signiﬁcant adverse effects, including valvular heart disease and
pulmonary hypertension.14–18 Prevalence estimates for valvular
heart disease vary widely. A meta-analysis of observational
studies indicated one in eight patients treated for more than
90 days with fenﬂuramine demonstrated valvular regurgitation.16
In a case–control study comparing 95 patients with primary
pulmonary hypertension to 355 controls, the use of anorexic drugs
(mainly dexfenﬂuramine and fenﬂuramine) was associated with
increased risk of developing primary pulmonary hypertension (OR
63; 95% CI 30–132).17 These adverse events led to the withdrawal
of both agents from the U.S. market in 1997.
A possible mechanism for the valvular disease associated with
appetite suppressants involves the stimulation of serotonin recep-
tors.19,20 The valve abnormalities seen with appetite suppressants
are similar to patients with carcinoid tumours and ergot exposure.
This occurs through stimulation of the 5-HT2b receptors on the
interstitial cells of the mitral and aortic valves. There are ample
numbers of these receptors on the valves, and they incite ﬁbroblast
mitogenesis. This leads to thickening of the heart valves and
valvular insufﬁciency. However, 5-HT2a and 5-HT2c are not
associated with valvulopathy. Fenﬂuramine binds weakly to 5-
HT2a, 5-HT2b and 5-HT2c receptors, but norfenﬂuramine, the
metabolite of fenﬂuramine, demonstrated high afﬁnity for 5-HT2b
and 5-HT2c receptors.21 The possible mechanism for pulmonary
hypertension related to appetite suppressant use is similar.22 The
5-HT1b receptor subtype and the 5-HT transporter are associated
with pulmonary hypertension and may be stimulated through the
non-selectivity of fenﬂuramine and its metabolites.23
Sibutramine. The FDA approved sibutramine in 1997 for obesity
after demonstrating signiﬁcant weight loss beneﬁts compared with
placebo. Sibutramine is a norepinephrine and serotonin reuptake
inhibitor9,11. These mechanisms are thought to reduce appetite and
induce thermogenesis. The increase in sympathetic activity asso-
ciated with its mechanism of action is thought to contribute to its
effects on blood pressure and heart rate.24 The product labeling
contained a contraindication for patients with a history of coronary
artery disease, heart failure, tachycardia, peripheral arterial occlu-
sive disease, arrhythmia or cerebrovascular disease, or inade-
quately controlled hypertension due to a risk of CV events and
substantial increases in blood pressure and heart rate.25
Due to concern for adverse CV events, the SCOUT trial was
initiated to examine the long-term effects of sibutramine on CV
outcomes in a high-risk population. Over 10 000 overweight or
obese patients, with age >55 and pre-existing CV disease, type 2
diabetes or both, were randomized to receive sibutramine or
placebo after a 6-week lead-in period. The primary outcome was a
composite endpoint of non-fatal myocardial infarction (MI), non-
fatal stroke, resuscitation after cardiac arrest or CV death. The
incidence of the primary outcome was 114% in the sibutramine
group vs. 100% in the placebo group (HR 116; 95% CI 103–131;
P = 002). The incidence of non-fatal MI and non-fatal stroke were
both signiﬁcantly elevated in the sibutramine group compared
with placebo, as well.26 After review of the preliminary results of
SCOUT, the FDA issued a safety alert that included a warning for
patients with CV disease. However, after ﬁnal publication of
SCOUT, the FDA asked the manufacturer to withdraw sibutr-
amine from the market completely.
Ephedrine and ephedra. Ephedrine and herbal ephedra may sup-
press appetite and stimulate thermogenesis by stimulating release
of norepinephrine into the synaptic cleft and stimulating beta-
adrenergic receptors.9 However, adrenergic stimulation of both
alpha- and beta-receptors is also associated with vasoconstriction
and cardiac stimulation leading to increased blood pressure and
heart rate.27 In 2000, Haller and Benowitz published a review of
140 reports of adverse events associated with ephedra products. Of
these reported, 31% were rated as deﬁnitely or probably related to
ephedra, with another 31% were possibly related. Forty-seven per
cent of these adverse effects were CV events including hyperten-
sion, palpitations, tachycardia, arrhythmias, MI, cardiac arrest or
stroke. Twenty-three events involved death or permanent disabil-
ity.28 A meta-analysis of 50 trials assessed the safety of ephedra
and ephedrine products. The pooled odds ratio for heart palpita-
tions was 229 (95% CI 127–432) with a non-signiﬁcant trend
towards increased odds of hypertension among patients receiving
ephedra or ephedrine products. The risk of adverse events
increased with higher doses of ephedra/ephedrine, but was not
signiﬁcant.29 In April 2004, the FDA declared ephedrine alkaloids
as adulterated substances because of the health risks to the
consumer and banned ephedra-containing dietary supplements
from the United States market.30
Ma huang is a Chinese herb derived from Ephedra species,
usually E. sinica. The herb is a source of ephedrine alkaloids,
consisting mostly of ephedrine and pseudoephedrine.27 The
pharmacokinetic parameters of ma huang capsules are similar to
ephedrine tablets and solution, with the exception of slower
absorption for the ma huang capsules.31
Ephedra alkaloids have been associated with thermoregulatory
dysfunction and have been involved in a number of deaths in
athletes. In February 2003, Steve Bechler, a professional baseball
© 2014 John Wiley & Sons Ltd Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 475–484
476
CV effects of weight loss pharmacotherapy C. P. Walter et al.
player, passed away during spring training due to heat stroke. The
use of an ephedra-based supplement was implicated in his death.32
The possible mechanisms for this thermodysregulation include
increased metabolism, increased creation of heat and elevated core
body temperature. Superﬁcial vasoconstriction may decrease the
capability of the body to redistribute heat sufﬁciently.33
Phenylpropanolamine. Phenylpropanolamine likely exhibits its
effects through central alpha-receptor stimulation in the hypothal-
amus, thus reducing food intake.11 Numerous published cases and
reports to the FDA suggest an association between phenylpropa-
nolamine and haemorrhagic stroke. A case–control study con-
ducted in the 1990s revealed phenylpropanolamine as a possible
risk factor for haemorrhagic stroke in women.34 The odds ratio was
1658 (95% CI, 151–18221; P = 002) for the association between
the use phenylpropanolamine in women and the risk of intracranial
haemorrhage. Although the overall risk of intracranial haemor-
rhage was low, the FDA believed the risk did not outweigh the
beneﬁt of these agents. Based on this information, the FDA deemed
phenylpropanolamine unsafe for use and requested all drug
companies discontinue products containing phenylpropanolamine.
Rimonabant. Although rimonabant was not withdrawn from the
market due to adverse CV effects, it was determined that the risks
outweighed the beneﬁts of this medication and did not make it to
the United States market. Rimonabant was an endocannabinoid-1
receptor antagonist. Potential mechanisms of weight loss included:
decrease in food intake by inhibiting cannabinoid receptors in the
CNS, increase in satiety signals, increased thermogenesis and
decreased lipogenesis.35 However, in June 2007, the FDA deter-
mined the risks of neurologic and psychiatric side effects
outweighed the weight loss beneﬁts of rimonabant and voted
against approval.
Current FDA-approved therapies
As shown by the drugs withdrawn from the market, cardiovas-
cular adverse effects are often a concern for new weight loss
agents. In this section, the efﬁcacy and cardiovascular safety of
current FDA-approved pharmacotherapies for the treatment of
obesity will be discussed.
Prior to recent FDA approvals, orlistat was the only weight loss
medication approved for long-term use. It is a reversible inhibitor
of both gastric and pancreatic lipases, which prevents the
absorption of dietary fat.9,11 At doses of 120 mg three times daily,
dietary fat absorption is reduced by approximately 30%. Olistat is
also available over-the-counter at a lower dose (60 mg three times
daily). Two systematic reviews reported increased weight loss in
patients receiving orlistat compared with placebo. Patients treated
with orlistat lost 29 kg or 29% more weight than placebo. All
trials demonstrated more orlistat patients achieving 5% weight
loss (21% more patients in the orlistat group, 95% CI 18–24%) and
10% weight loss (12% more patients in the orlistat group, 95% CI
9–14%).36,37 The longest trial to date spanned four years and
included over 3000 patients. Patients in the orlistat group expe-
rienced signiﬁcantly more weight loss than the control group
(58 lb vs. 30 lb, P < 0001) at 4 years. Signiﬁcantly, more orlistat
patients achieved at least 5% and at least 10% weight loss
compared with placebo, respectively (≥5%: 528% vs. 373%,
P < 0001; ≥10%: 263% vs. 156%, P < 0001).38 Orlistat’s side
effect proﬁle is largely associated with its effects on the gastroin-
testinal tract. Side effects include: abdominal pain, bloating,
ﬂatulence, diarrhoea and decreased absorption of fat-soluble
vitamins. The CV proﬁle of orlistat is generally favourable and
lacks the adverse CV proﬁle of other weight loss agents.
Phendimetrazine, phentermine, diethylpropion and benzphet-
amine are controlled amphetamine or amphetamine-like ana-
logues available for short-term use, which is usually interpreted as
up to 12 weeks. These sympathomimetic amines may stimulate
the release of neurotransmitters acting centrally on the satiety
centre of the brain and increase energy expenditure.9,11 Limited
information from large randomized controlled trials exists regard-
ing long-term efﬁcacy and safety of these medications. Because of
this, the use of these agents is limited in the management of obese
or overweight patients.39 They are often associated with sympat-
homimetic CV adverse effects.40,41 These include palpitations,
tachycardia and elevations in blood pressure. It is recommended to
use these agents with extreme caution in patients with hyperten-
sion and CV disease.
New agents
It had been over a decade since the FDA approved a medication
for weight loss. Orlistat was approved for long-term weight loss in
1999. However, this changed in 2012 with the approval of two new
agents for weight loss: lorcaserin and phentermine/topiramate.
Lorcaserin. Lorcaserin (Belviq, Arena Pharmaceuticals, Zoﬁngen,
Switzerland) is a selective 5-HT2c receptor agonist. It is hypoth-
esized lorcaserin selectively activates these receptors on anorexi-
genic pro-opiomelanocortin neurons in the hypothalamus, and
activation of these receptors stimulates satiety and decrease food
consumption.42,43 The exact mechanism is unknown. Lorcaserin
potency (EC50) and binding afﬁnity (Ki) for human 5-HT2a, 5-
HT2b and 5-HT2c receptor subtypes are as follows: EC50 = 5-
HT2c 39 nM, 5-HT2b 2380 nM and 5-HT2a 553 nM; Ki = 5-HT2c
13 nM, 5-HT2b 147 nM, 5-HT2a 92 nM.44 Lorcaserin is more potent
and has a greater binding afﬁnity for the 5-HT2c receptor. Based
on these data, it is unlikely that lorcaserin would activate the 5-
HT2b receptor at therapeutic doses. This selectivity differentiates
lorcaserin from fenﬂuramine and dexfenﬂuramine. Whereas lor-
caserin is selective in its agonism, fenﬂuramine and dexfenﬂur-
amine are non-speciﬁc agents. Their metabolites are potent 5-HT2b
agonists associated with valvulopathy.45 Theoretically, this selec-
tivity allows for the weight loss beneﬁt of 5-HT2c activation
without the adverse effects of other serotonin receptor stimulation.
Lorcaserin was studied in a series of trials in addition to diet and
exercise counselling.
The BLOOM trial was a 2-year, randomized, placebo-controlled,
double-blind trial that examined the efﬁcacy and safety of
lorcaserin for weight loss. This study randomized 3182 obese or
overweight adults [BMI 30–45 or BMI 27–45 with at least one
coexisting condition (hypertension, dyslipidemia, CV disease,
impaired glucose tolerance or sleep apnoea)] to receive lorcaserin
10 mg twice daily plus diet and exercise counselling or placebo
plus diet and exercise counselling for 52 weeks. At 52 weeks, the
treatment group was further randomized to continue lorcaserin or
initiate placebo. At one year, signiﬁcantly more patients in the
lorcaserin group, compared with the placebo group, achieved ≥5%
weight loss than in the placebo group (475% vs. 203%, P < 0001),
lost a higher percentage of the baseline weight (581% vs. 216%,
P < 0001) and achieved ≥10% weight loss from baseline (226% vs.
77%, P < 0001). At one year, patients in the lorcaserin group lost
a mean of 58 kilograms (kg), compared with a mean of 22 kg in
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the placebo group (P < 0001). More patients who continued
lorcaserin for the second year maintained weight loss (679% vs.
503%, P < 0001).46 (Table 1)
Overall, there were no signiﬁcant differences between lorcaserin
and placebo for adverse CV outcomes. At one year, there was no
statistical difference between the rates of valvulopathy between
the two groups (27% vs. 23%, P = 070). This continued at year 2
as well (26% vs. 27%). Valvular insufﬁciency scores (mitral and
aortic valves) and change in mean pulmonary-artery systolic
pressure were not statistically different between the study groups
as well. However, power was not met for FDA-deﬁned valvulop-
athy due to an overestimation of effect size. This decreased the
statistical power to rule out relative risk of FDA-deﬁned valvul-
opathy for lorcaserin to 60%, below the required 80%. This limits
the ability to draw conclusions regarding valvulopathy from this
trial.46
Blood pressure, total cholesterol, triglycerides, fasting glucose,
glycated haemoglobin, CRP and ﬁbrinogen improved signiﬁcantly
from baseline to one year in the lorcaserin group compared with
placebo.46 (Table 2)
A follow-up trial to BLOOM, the BLOSSOM trial, was con-
ducted in 4008 patients to determine the optimal dose of lorcaserin
for both efﬁcacy and safety. Patients received either lorcaserin
10 mg daily, lorcaserin 10 mg twice daily or placebo. All patients
received diet and exercise counselling. The results of this trial
paralleled the results of the BLOOM trial. They found the weight
loss associated with lorcaserin appeared to be dose-dependent.
The patients receiving lorcaserin achieved signiﬁcantly more
weight loss than placebo with a trend towards increased weight
loss with the twice daily dose. Mean weight loss in patients treated
with lorcaserin 10 mg twice daily was similar to that in BLOOM.
Percentage of patients achieving ≥5% weight loss, ≥10% weight
Table 1. Efﬁcacy endpoints (1-year results, P-value vs. placebo)46,47,51
Lorcaserin Phentermine/Topiramate
BLOOM BLOSSOM CONQUER
Placebo 10 mg BID Placebo 10 mg BID 10 mg QD Placebo 75 mg/46 mg 15 mg/92 mg














































Table 2. Change in metabolic and cardiovascular endpoints (1-year results)46,47,51
Lorcaserin Phentermine/Topiramate
BLOOM BLOSSOM CONQUER
Placebo 10 mg BID Placebo 10 mg BID 10 mg QD Placebo 75 mg/46 mg 15 mg/92 mg
Waist circumference (cm) 39  02 68  02* 41  02 63  02* 58  03* 24  03 76  04* 92  03*
BMI 08  01 21  01* 10  01 21  01* 17  01*
Blood Pressure (mm Hg)
Systolic 08  03 14  03* 12  03 19  03 13  04 24  05 47  04* 56  05*
Diastolic 06  02 11  02* 14  02 19  02 11  03 27  03 34  04 38  03*
Cholesterol (%)
Total 06  03 09  03* 00  03 07  03 13  05* 33  05 49  07* 63  05*
LDL 40  06 29  06* 17  05 03  05 01  07 41  09 37  11 69  09*
HDL 02  03 01  03 13  04 37  04* 35  06* 12  07 52  09* 68  07*
Triglycerides (%) 01  10 62  10* 09  09 43  09* 55  13* 47  17 86  22* 106  17*
Fasting glucose (mg/dL) 11  03 08  03* 013  003 001  004* 007  003*
Glycated hemoglobin (%) 003  001 004  001* 014  001 019  001 017  001 01  003 0  003* 01  003*
Heart rate (beats/min) 16  04 20  03* 16  02 23  02 11  03
*P-value <005 compared to placebo.
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loss and mean weight change in kilograms were signiﬁcantly
improved with the twice daily dosing scheme compared with
daily dosing (P < 001).47 (Table 1)
The signiﬁcant differences in cardiometabolic endpoints seen in
the BLOOM trial were not signiﬁcant in BLOSSOM. Total
cholesterol and LDL-C were not statistically different from
placebo. However, both triglycerides and HDL-C were signiﬁ-
cantly improved compared with placebo for both dosing schemes,
with blood pressure signiﬁcantly improved with the twice daily
dosing scheme. The incidence of cardiac valvulopathy was not
statistically different between the treatment and placebo groups.
This trial was not powered to detect a difference with cardiac
valvulopathy, and more data are needed before major conclusions
can be drawn regarding valvulopathy.47 (Table 2)
BLOOM-DM examined the weight loss efﬁcacy and safety of
lorcaserin in patients with type 2 diabetes mellitus. Patients were
eligible if they had a diagnosis of type 2 diabetes treated with
metformin, a sulfonylurea, or both, had glycated haemoglobin of
7–10% at screening and had a BMI between 27 and 45 kg/m2. In
this study, 604 patients were randomized to receive placebo,
lorcaserin 10 mg daily or lorcaserin 10 mg twice daily. All patients
received diet and exercise counselling. Signiﬁcantly, more patients
achieved ≥5% weight loss in the lorcaserin twice daily or the
lorcaserin daily groups compared with placebo (375% vs. 447%
vs. 161%, P < 0001 compared to placebo). Per cent weight change
in the lorcaserin twice daily, lorcaserin daily and placebo was
45  035%, 50  05% and 15  036%, respectively,
(P < 0001 compared with placebo for each). Glycated haemoglo-
bin decreased 09  006 for lorcaserin twice daily, 10  009 for
lorcaserin daily and 04  006 for placebo (P < 0001 compared to
placebo for each). There was a non-signiﬁcant increase is valvul-
opathy based on echocardiogram in the lorcaserin groups; how-
ever, the study was not powered to detect signiﬁcant difference
with this outcome. At 24 weeks, 19% of placebo patients had new
valvulopathy whereas 39% (P = 0395, compared to placebo) in
the lorcaserin daily group and 25% (P = 0750 compared to
placebo) in the lorcaserin twice daily groups had new valvulop-
athy. At 52 weeks, 05% experienced new valvulopathy in the
placebo group, whereas 25% (P = 0187, compared with placebo)
in the lorcaserin daily group and 29% (P = 0122, compared with
placebo) in the lorcaserin twice daily group had these ﬁndings.48
Like most weight loss trials, these studies included high rates of
study drug discontinuation. This requires imputation methods to
account for the missing data, and it is unclear which statistical
method to account for this missing data is most accurate to predict
the efﬁcacy of lorcaserin clinically. Also, patients with depression
or treated with selective serotonin reuptake inhibitors were
excluded in these trials and the majority of the population was
female. In BLOOM and BLOSSOM, the male participants were
<20%. These studies do not address the effects of lorcaserin in a
general population, and further clinical experience will be neces-
sary. Lastly, to fully assess the risk cardiac valvulopathy in
patients receiving lorcaserin, larger trials will be needed.
In September 2010, the FDA’s Endocrinologic and Metabolic
Drugs Advisory Committee voted against approval because of
preclinical carcinogenicity concerns with minimal weight loss
found in the clinical trials. The FDA required more information
regarding these concerns. In December 2011, Arena Pharmaceu-
ticals, the manufacturer of Belviq, submitted data in response to
these concerns that included ofﬁcial consensus on the preclinical
data and ﬁnal analysis included the ﬁnal data from BLOOM-DM.49
This report provided a pooled analysis of the valvulopathy data
from the three clinical, phase 3 trials. At 52 weeks, the proportion
of patients with an increase from baseline valvular regurgitation
was signiﬁcantly increased in mitral and tricuspid regurgitation
and in all valves combined. Another pooled analysis of FDA-
deﬁned valvulopathy included data from the three, phase 3,
clinical trials. The pooled relative risk was 116 (95% CI 081 to
167) based on these three trials.49 (Tables 3 and 4)
Based on the results of these studies, the FDA granted approval
for lorcaserin for chronic weight loss management in addition to
diet and exercise. Because the effect of lorcaserin on adverse CV
outcomes, speciﬁcally valvulopathy, has yet to be extensively
Table 3. Patients with increase in valvular regurgitation from
baseline (excluding absent to trace) (1-year results with last
observation carried forward)49
Lorcaserin
10 mg BID (%) Placebo (%)
Relative risk
(95% CI) P-value
Aortic 134 145 092 (059–144) 071
Mitral 992 819 121 (102–143) 003
Pulmonic 1700 1551 110 (097–124) 014
Tricuspid 1218 988 123 (106–144) 0008
Any valve 3237 2824 115 (106–124) 0001
Adapted from Belviq FDA documentation.

















FDA-deﬁned valvulopathya, n (%) 34 (266) 28 (235) 24 (199) 23 (199) 6 (286) 1 (048)
Relative risk (95% CI) 113 (069 to 185) 100 (057 to 175) 597 (073 to 4917)
Pooled relative risk (95% CI) 116 (081 to 167)
Adapted from Belviq FDA documentation.
aFDA-deﬁned valvulopathy is deﬁned as mild or greater aortic insufﬁciency and/or moderate or greater mitral insufﬁciency.
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examined, the FDA will require post-marketing studies involving
CV outcomes to determine the risk of major adverse CV events.
The prescribing information includes warnings and precautions
regarding speciﬁc patient populations. It recommends using
lorcaserin with caution in patients with congestive heart failure
(CHF), valvular disease and pulmonary hypertension because
studies did not include these patient populations. Data also
suggest 5HT2b serotonin receptors may be overexpressed in
CHF.44,50 The high afﬁnity of lorcaserin for the 5-HT2c receptor
compared with the other 5-HT2 receptors may be lost if the 5-HT2
receptor ratio is altered. Due to the potential risk of adverse CV
outcomes in these populations, use of lorcaserin is not recom-
mended.
Phentermine/Topiramate. Phentermine/Topiramate (QsymiaTM, VI-
VUS Inc., Mountain View, CA, USA) is a low-dose, controlled
release, combination product. Phentermine is a centrally acting
sympathomimetic, similar to amphetamine, which stimulates
release of norepinephrine from the hypothalamus.51,52 It was ﬁrst
approved for the short-term treatment of obesity in 1959. Topira-
mate is approved for the treatment of epilepsy and migraine
prophylaxis. Topiramate was initially studied for weight loss as a
single agent; however, the dose-dependent neuropsychiatric
effects, such as memory and mood effects, prevented the realiza-
tion of this indication. Topiramate blocks neuronal voltage-
dependent sodium channels, boosts GABA activity, antagonizes
glutamate receptors and inhibits carbonic anhydrase.53 However,
the exact mechanism in weight loss is largely unknown. A possible
mechanism associated with topiramate includes decreased caloric
intake, as indicated by human studies, but other mechanisms may
contribute. Animal studies indicate other mechanisms may include
increased energy expenditure, decreased food intake, decreased
energetic efﬁciency, increased thermogenesis and/or increased
insulin sensitivity.53–55 There appears to be a possible synergistic
effect when combined. However, this has not been examined
clinically. The combination is formulated to achieve peak exposure
to each drug separately. The peak exposure of the immediate-
release phentermine occurs in the morning, whereas the peak
exposure to the extended-release topiramate occurs in the late
afternoon or evening to coincide with late afternoon/evening
hunger.56
CONQUER was a randomized, double-blind, placebo-con-
trolled trial that examined the efﬁcacy and safety of phenter-
mine/topiramate controlled release combination for weight loss in
overweight and obese individuals with two or more risk factors
(hypertension, dyslipidemia, diabetes or prediabetes, or abdomi-
nal obesity). In this 1-year trial, 2487 patients were randomized to
receive phentermine 75 mg/topiramate 46 mg once daily (P/T
75/46), phentermine 15 mg/topiramate 92 mg once daily (P/T
15/92) or placebo. Both doses of phentermine/topiramate had
signiﬁcantly improved weight loss compared with placebo. At the
end of the study, patients receiving placebo lost signiﬁcantly less
weight than either the lower dose phentermine/topiramate com-
bination or the higher-dose combination, respectively (14 kg vs.
84 kg vs. 102 kg, P < 00001 for each compared to placebo).
Signiﬁcantly, more patients achieved ≥5% weight loss compared
with placebo (21%) in both treatment groups (lower dose 62%,
P < 00001; higher dose 70%, P < 00001) (Table 1). In terms of the
cardiometabolic endpoints, both treatment groups demonstrated
signiﬁcantly reduced waist circumference, blood pressure, total
cholesterol, triglycerides, fasting glucose, glycated haemoglobin
and C-reactive protein (CRP) compared with placebo (Table 2).
These reductions were more evident in patients with pre-existing
risk factors. Average heart rate was increased in the high-dose
treatment group compared with baseline (17 beats per minute;
95% CI 09 to 24; P < 00001). More patients in the treatment
groups experienced increases of more than 10 beats per minute at
consecutive visits as well.51
The SEQUEL trial was a 52-week extension of the CONQUER
study. In this trial, 866 patients continued their originally
randomized treatment for a total of 108 weeks. The results from
the CONQUER trial were sustained in SEQUEL. Both doses of
phentermine/topiramate signiﬁcantly improved weight loss com-
pared with placebo, as well as cardiometabolic markers with
decreased utilization of medications to treat the cardiometabolic
disease states. Percentage change from baseline body weight was
18%, 93% and 105% for placebo, P/T 75/46 and P/T 15/
92, respectively (P < 00001 for each compared with placebo).
Absolute mean weight loss was 21 kg, 96 kg and 109 kg for
placebo, P/T 75/46 and P/T 15/92, respectively (P < 00001 for
each compared with placebo).57
EQUIP examined the efﬁcacy and safety of phentermine/
topiramate in patients with class II or class III obesity (BMI ≥35).
Patients were randomized to receive placebo, phentermine/topi-
ramate 375 mg/23 mg (P/T 375/23) or P/T 15/92 in addition to
a reduced calorie diet. Both treatment groups lost signiﬁcantly
more body weight compared with placebo at 56 weeks (P < 00001
for each), as well as signiﬁcantly more patients achieving a weight
loss of >5% (P < 00001 for each). Both the low-dose and high-dose
combination demonstrated improved waist circumference and
blood pressure compared to placebo, with the high-dose treatment
demonstrating improved total cholesterol, LDL-c, HDL, triglyce-
rides and fasting serum glucose. The high-dose treatment
increased heart rate from baseline by 12 beats per minute
(P = 00830), which may be ascribed to the sympathomimetic
activity of phentermine.52
Table 5. Mean changes in surrogate cardiovascular endpoints (1-year results)56
Placebo
n = 1532
P/T 375 mg/23 mg
n = 234
P/T 75 mg/46 mg
n = 488
P/T 15 mg/92 mg
n = 1553
Systolic BP (mm Hg) 21 (1401) 33 (1195) P = 02322 52 (1477) P < 00001 52 (1448) P < 00001
Diastolic BP (mm Hg) 19 (961) 09 (829) P = 01362 33 (987) P = 00044 29 (940) P = 00023
Heart rate (beats/minute) 00 (1019) 13 (1032) P = 00688 06 (1018) P = 02933 16 (1028) P < 00001
Rate-pressure product 015 (167) 009 (154) P = 05470 030 (173) P = 01686 019 (169) P = 03306
Mean change (SD), P-value compared with placebo.
Adapted from Qsymia FDA documentation.
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Like lorcaserin, phentermine/topiramate trials also had high
dropout rates, lack of population diversity and high numbers of
female participants.
Initially, in 2010, the FDA rejected phentermine/topiramate due
to concerns for adverse effects. The FDA required more informa-
tion regarding the elevations in heart rate and its relation to
adverse CV events. In response to the FDA’s request, VIVUS, the
drug’s manufacturer, evaluated pooled data from the original
studies to examine adverse CV events related to the increase in
heart rate associated with phentermine/topiramate. (Table 5)
The report included analysis of heart rate, cardiac arrhythmias,
rate-pressure product, major CV outcomes and mortality risk
scores. The predictor of increased heart rate was baseline heart
rate. Patients with lower baseline heart rates experienced the
largest increase in heart rates. Cardiac arrhythmic effects occurred
more frequently in the P/T 15/92 (47%) and P/T 75/46 (42%)
groups compared with placebo (18%). The majority of these
events were palpitations, increased heart rate and tachycardia. The
change in rate-pressure product (RPP) was not statistically
different when comparing treatment groups with placebo. Increase
in RPP is associated with an increase in myocardial oxygen
demand, which may lead to adverse cardiac events. Treatment
groups were associated with a decrease in RPP.56
Additionally, VIVUS used risk models, including Cooper Clinic
Mortality Risk Index, to assess the overall all-cause mortality
effects of phentermine/topiramate. The Cooper Clinic Mortality
Risk Index accounts for the following factors: age, heart rate, blood
pressure, diabetic status, smoking status and body mass index
(BMI). A drawback to this risk model is that validation occurred in
a population that consisted only of men. When applied separately
to the male and female patients of the 1-year cohort, it demon-
strated a signiﬁcant reduction in mortality risk scores in the
higher-dose groups in both male and female patients. However,
our ability to draw conclusions from these data is limited because
a risk model was utilized instead of a randomized, controlled trial
powered to detect differences in mortality.56
Lastly, they analysed a variety of major CV outcomes. These
included composite of CV death, MI and stroke; composite of CV
death, stroke, coronary revascularization and unstable angina
(Jupiter MACE); and other composite major adverse CV events.
Hazard ratios were less than one for all composite CV outcomes
examined; however, due to the low number of events, the 95%
conﬁdence intervals were wide. There were a limited number of
adverse CV events in the studies making it difﬁcult to draw
conclusions regarding the effect of phentermine/topiramate on
these outcomes. The authors were unable to ﬁnd a connection
between heart rate and adverse CV events.56 (Table 6)
In July 2012, after review of the new analysis, the FDA approved
phentermine/topiramate for chronic weight management in addi-
tion to diet and exercise. However, like lorcaserin, the FDA will
require post-marketing studies to assess long-term CV outcomes
and risk of major adverse CV events. The prescribing information
includes a warning for increased heart rate and advises monitoring
for patients with cardiac or cerebrovascular disease. If palpitations,
high heart rates at rest or signiﬁcant increases in heart rate are
noted, it is recommended to decrease dose or discontinue therapy.
Because phentermine/topiramate has not been studied in patients
with recent or unstable cardiac or cerebrovascular disease, use is
not recommended in these patient populations.
Pipeline agents
Naltrexone/Bupropion was submitted to the FDA for approval in
2010. In the FDA’s response letter, they asked the company for a
randomized, double-blind, placebo-controlled trail to assess the
risk of major adverse CV events.
The COR-I (Contrave Obesity Research I) trial assessed the
efﬁcacy and safety of sustained-release naltrexone/bupropion for
weight loss in 1742 overweight and obese patients (BMI 30–45 kg/
m2 or BMI 27–45 with dyslipidemia or hypertension). Exclusion
criteria included type 1 or 2 diabetes, and cerebrovascular, CV,
hepatic or renal disease. Patients were randomized to receive SR
naltrexone/bupropion 16 mg/180 mg twice daily, SR naltrexone/
bupropion 8 mg/180 mg twice daily or placebo twice daily for
56 weeks. Compared with placebo, patients who received SR
naltrexone/bupropion achieved signiﬁcantly more weight loss.
This was evident in both the high-dose group (61% vs. 13%,
P < 00001 compared with placebo) and the low-dose group (50%
vs. 13%, P < 00001 compared with placebo). Patients who
achieved a weight loss of ≥5% were also signiﬁcantly higher in
both treatment groups compared to placebo. In the high-dose
group, 48% of patients attained this endpoint compared to 16% in
the placebo arm (P < 00001). In the low-dose group, 39% of
patients lost ≥5% of their baseline weight (P < 00001 compared
with placebo). Patients in both treatment groups had a signiﬁcant
increase in HDL and decrease in triglycerides and CRP compared
with placebo with no signiﬁcant difference in LDL at 56 weeks.
However, there was a transient increase in mean blood pressure










n = 2581 Hazard ratiod 95% CI
CV death, MI, stroke 03 05 03 02 03 084 026–264
Jupiter MACEa 06 05 03 03 03 055 021–142
FDA MACEb 06 05 03 03 03 049 019–125
Modiﬁed FDA MACEc 08 05 06 05 05 062 029–133
Adapted from Qsymia FDA documentation. MACE = major adverse cardiovascular events.
aCV death, MI, stroke, coronary revascularization and unstable angina.
bCV death, MI, stroke, coronary revascularization, unstable angina and congestive heart failure.
cCV death, ACS, cerebrovascular events, coronary revascularization, hospitalization for heart failure, stent thrombosis, hospitalization for other CV causes,
carotid artery revascularization, peripheral vascular revascularization, lower extremity amputation, hospitalization for cardiac arrhythmia.
dHazard ratio is from a univariate Cox proportional hazards regression analysis comparing P/T Total to placebo.
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from baseline in the treatment groups, and blood pressure was
increased compared with placebo in both treatment groups.58 A
trial investigating cardiovascular outcomes of naltrexone–bupro-
pion in obese and overweight patients with cardiovascular risk
factors is currently ongoing.59
There are medications indicated for type 2 diabetes that are
associated with the potential for weight loss as well. These
medications include glucagon-like peptide-1 (GLP-1) receptor
agonists (liraglutide and exenatide), amylinomimetic (pramlintide)
and metformin. Several of these agents are either undergoing or
have recently completed clinical trials in obese patients without
diabetes.59
Small studies have demonstrated GLP-1 receptor agonists have
the potential to increase satiety, decrease food intake, and induce
weight loss.60,61 However, emerging evidence suggests these agents
have potential for cardiovascular benets beyond blood glucose
control and weight loss as well.62 However, this evidence is
preliminary and requires further investigation in large clinical trials.
Other agents currently in clinical trials include: bupropion/
zonisamide, pramlintide/metreleptin, canagliﬂozin, cetilistat and
velneperit.59
WHAT IS NEW AND CONCLUSION
Obesity continues to adversely affect a large portion of the
population, and its prevalence continues to rise. It is also a risk
factor for CV disease, and new treatment options are needed.
However, safety issues, speciﬁcally adverse CV events, have
signiﬁcantly inﬂuenced the ability of weight loss pharmacothera-
pies to make it to or remain on the market. This was evident in the
decade long gap between FDA approvals of new weight loss
medications. The market drought ended with the approval of
lorcaserin and phentermine/topiramate. In Table 1, we compare
the efﬁcacy outcomes across the main trials for each medication. It
appears phentermine/topiramate may be a slightly more potent
weight loss agent when comparing efﬁcacy outcomes across the
trials. Numerically, phentermine/topiramate had a greater abso-
lute weight loss and per cent weight loss from baseline, and more
patients achieved ≥5% weight loss and ≥10% weight loss than
lorcaserin. However, it is unclear whether this comparison would
continue in a clinical trial. The differences in the methodology of
the trials, patient populations, and diet and exercise interventions
limit the ability to make comparisons across the studies. It is
important to note that there is no head-to-head comparison trial
for these two agents and any comparison made in this paper of the
two agents is only hypothesis generating.
The new weight loss medications potentially have serious risks
associated with their use. If these agents are used, it is important
they are used as indicated in the product labelling. One major
concern is these medications may be used inappropriately,
including use for minor cosmetic weight loss in patients with a
BMI that does not meet the criteria for use. Also, patients who
receive these medications need to be monitored appropriately for
efﬁcacy. If these efﬁcacy criteria (as indicated in product labelling)
are not met, discontinuation of the medication should occur, as it is
unlikely the patient will achieve weight loss if continued. In both
these situations, the risks likely outweigh the beneﬁts of use, or
continued use, of the medications.
Each new agent has unique cardiovascular concerns, and it is
difﬁcult to determine, based on adverse effects, which agent would
be preferred. There are major concerns regarding use in patients
with cardiovascular disease, and there are still many issues that
need to be addressed. These include long-term CV outcomes
studies with and without high-risk CV patients, before these
agents can be recommended in these patient populations. It is yet
to be determined whether modest weight loss beneﬁt of these new
agents outweighs the CV risks.
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